{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:23:17Z","timestamp":1790706197093,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1097\/01.crd.0000154790.42283.a1","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T09:01:44Z","timestamp":1108112504000},"page":"76-79","source":"Crossref","is-referenced-by-count":60,"title":["HMG-CoA Reductase Inhibitors and Coenzyme Q10"],"prefix":"10.1097","volume":"13","author":[{"given":"James J.","family":"Nawarskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease.","volume":"164","author":"Wilt","year":"2004","journal-title":"Arch Intern Med"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.","volume":"57","author":"Cheung","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"R5-6-20210203","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions.","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions. Use of cerivastatin and risk of rhabdomyolysis.","volume":"292","author":"Psaty","year":"2004","journal-title":"JAMA"},{"issue":"suppl","key":"R8-6-20210203","first-page":"S55","article-title":"The essential functions of coenzyme Q.","volume":"71","author":"Crane","year":"1993","journal-title":"Clin Investig"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of coenzyme Q10.","volume":"20","author":"Crane","year":"2001","journal-title":"J Am Coll Nutr"},{"issue":"suppl","key":"R10-6-20210203","first-page":"S116","article-title":"Perspectives on therapy of cardiovascular disease with coenzyme Q10 (ubiquinone).","volume":"71","author":"Mortensen","year":"1993","journal-title":"Clin Investig"},{"key":"R11-6-20210203","first-page":"655","article-title":"Cardiovascular Pharmacotherapeutics, 2nd ed.","author":"Frishman","year":"2003"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans.","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00194398","article-title":"Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.","volume":"46","author":"Laaksonen","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-6-20210203","first-page":"324","article-title":"Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.","volume":"49","author":"Miyake","year":"1999","journal-title":"Arzneim-Forsch\/Drug Res"},{"issue":"suppl","key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0098-2997(97)00014-9","article-title":"Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.","volume":"18","author":"Mortensen","year":"1997","journal-title":"Mol Aspects Med"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio.","volume":"42","author":"DePinieux","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jcp.46.11.1055","article-title":"Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.","volume":"46","author":"Watts","year":"1993","journal-title":"J Clin Pathol"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-2275(20)41990-X","article-title":"Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.","volume":"32","author":"Elmberger","year":"1991","journal-title":"J Lipid Res"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl","key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"s187","DOI":"10.1016\/0098-2997(94)90028-0","article-title":"Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.","volume":"15","author":"Bargossi","year":"1994","journal-title":"Mol Aspects Med"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.","volume":"61","author":"Rundek","year":"2004","journal-title":"Arch Neurol"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1067\/mhj.2001.116762","article-title":"The effect of pravastatin and atorvastatin on coenzyme Q10.","volume":"142","author":"Bleske","year":"2001","journal-title":"Am Heart J"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2004.07.121","article-title":"Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.","volume":"94","author":"Silver","year":"2004","journal-title":"Am J Cardiol"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(89)91108-2","article-title":"Lovastatin, isoprenes and myopathy.","volume":"ii","author":"Walravens","year":"1989","journal-title":"Lancet"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome.","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"key":"R27-6-20210203","first-page":"1225","article-title":"HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.","volume":"257","author":"Smith","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00005072-199309000-00012","article-title":"Experimental lovastatin myopathy.","volume":"52","author":"Waclawik","year":"1993","journal-title":"J Neuropathol Exp Neurol"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0022-510X(92)90273-N","article-title":"Experimental simvastatin-induced myopathy in rabbits.","volume":"113","author":"Nakahara","year":"1992","journal-title":"J Neurol Sci"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1998.8491","article-title":"Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.","volume":"152","author":"Nakahara","year":"1998","journal-title":"Toxicol Appl Pharmacol"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am J Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.crd.0000154790.42283.a1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:23:58Z","timestamp":1620937438000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200503000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000154790.42283.a1","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}